LA JOLLA, Calif., March 11, 2013 Sanford-Burnham Medical Research Institute (Sanford-Burnham) and Mayo Clinic signed a new collaborative agreement to build a pipeline of therapeutic drugs aimed at a variety of diseases with serious unmet medical needs. Under this agreement, Mayo Clinic scientists will work with researchers in Sanford-Burnham's Conrad Prebys Center for Chemical Genomics (Prebys Center) to conduct early-stage drug discovery, including assay development, high-throughput screening, and lead identification. Sanford-Burnham, an independent research institute, is recognized for establishing novel collaborations with clinical organizations to expedite early-phase drug discovery.
The agreement combines Mayo Clinic's clinically relevant targets with Sanford-Burnham's discovery platform in a translational initiative aimed at advancing a portfolio of projects through the initial stages of drug discovery. The new agreement builds on a yearlong pilot phase and expands the number and scope of drug discovery projects derived from Mayo Clinic researchers that are being conducted at Sanford-Burnham.
"We're looking forward to further engaging with our Mayo Clinic collaborators as we develop innovative screens to identify chemical compounds that modulate the activity of clinically relevant targets," said Michael Jackson, Ph.D., vice president of drug discovery and development at Sanford-Burnham. "If successful, these compounds will form the basis of completely novel'first in class'therapies for devastating diseases such as cancer, Alzheimer's, and others."
In Sanford-Burnham's Prebys Center, Jackson and a team of researchersmany of them recruited from the pharmaceutical industryuse state-of-the-art, ultra-high throughput screening systems to sift through the Institute's compound library, recognized as one of the largest collections in the nonprofit research community.
"The Mayo Clinic-Sanford-Burnham collaboration provides
|Contact: Heather Buschman|
Sanford-Burnham Medical Research Institute